Back to results
US 11,376,243 B2Granted
Pharmaceutical compositions
AssigneeXspray Pharma AB
InventorsMagnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
Claims30
A composition, comprising:
- (a) particles comprising
- (i) amorphous nilotinib or a salt thereof;
- and
- (ii) at least one polymeric stabilizing and matrix-forming component selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinylpyrrolidone, polyvinyl acetate phthalate, copolyvidone, crospovidone, methacrylic acid and ethylacrylate copolymer, methacrylate acid and methyl methacrylate copolymer, DL lactide/glycolide copolymer, poly DL-lactide, cellulose acetate phthalate, carbomer homopolymer Type A, carbomer homopolymer Type B, an aminoalkyl methacrylate copolymer, and a poloxamer;
- wherein the particles exclude at least one pharmaceutically acceptable solubilizer.
2 more elements
A tablet or capsule comprising:
- (a) particles comprising
- (i) amorphous nilotinib or a salt thereof;
- and
- (ii) at least one polymeric stabilizing and matrix-forming component selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinylpyrrolidone, polyvinyl acetate phthalate, copolyvidone, crospovidone, methacrylic acid and ethylacrylate copolymer, methacrylate acid and methyl methacrylate copolymer, DL lactide/glycolide copolymer, poly DL-lactide, cellulose acetate phthalate, carbomer homopolymer Type A, carbomer homopolymer Type B, an aminoalkyl methacrylate copolymer, and a poloxamer;
- wherein the particles exclude at least one pharmaceutically acceptable solubilizer;
- and
- (b) an excipient.
4 more elements
Dependencies are inferred from the claim text.